Psychopharmacology

, Volume 198, Issue 4, pp 587–603

Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Δ-9-tetrahydrocannabinol in humans

  • Deepak Cyril D’Souza
  • Gabriel Braley
  • Rebecca Blaise
  • Michael Vendetti
  • Stephen Oliver
  • Brian Pittman
  • Mohini Ranganathan
  • Savita Bhakta
  • Zoran Zimolo
  • Thomas Cooper
  • Edward Perry
Original Investigation

Abstract

Introduction

Cannabinoids produce a spectrum of effects in humans including euphoria, cognitive impairments, psychotomimetic effects, and perceptual alterations. The extent to which dopaminergic systems contribute to the effects of Δ-9-tetrahydrocannabinol (Δ-9-THC) remains unclear. This study evaluated whether pretreatment with a dopamine receptor antagonist altered the effects of Δ-9-THC in humans.

Materials and methods

In a 2-test-day double-blind study, 28 subjects including healthy subjects (n = 17) and frequent users of cannabis (n = 11) were administered active (0.057 mg/kg) or placebo oral haloperidol in random order followed 90 and 215 min later by fixed order intravenous administration of placebo (vehicle) and active (0.0286 mg/kg) Δ-9-THC, respectively.

Results

Consistent with previous reports, intravenous Δ-9-THC produced psychotomimetic effects, perceptual alterations, and subjective effects including “high.” Δ-9-THC also impaired verbal recall and attention. Haloperidol pretreatment did not reduce any of the behavioral effects of Δ-9-THC. Haloperidol worsened the immediate free and delayed free and cued recall deficits produced by Δ-9-THC. Haloperidol and Δ-9-THC worsened distractibility and vigilance. Neither drug impaired performance on a motor screening task, the Stockings of Cambridge task, or the delayed match to sample task. Frequent users had lower baseline plasma prolactin levels and blunted Δ-9-THC induced memory impairments.

Conclusions

The deleterious effects of haloperidol pretreatment on the cognitive effects of Δ-9-THC are consistent with the preclinical literature in suggesting crosstalk between DAergic and CBergic systems. However, it is unlikely that DA D2 receptor mechanisms play a major role in mediating the psychotomimetic and perceptual altering effects of Δ-9-THC. Further investigation is warranted to understand the basis of the psychotomimetic effects of Δ-9-THC and to better understand the crosstalk between DAergic and CBergic systems.

Keywords

Schizophrenia Cannabinoids Dopamine Antipsychotic Cognition Memory Addiction Attention Haloperidol Endocrine 

Supplementary material

213_2007_1042_MOESM1_ESM.doc (36 kb)
Table S1Motor results (means [±SD]) (DOC 36.0 KB)

References

  1. Agurell S, Halldin M, Lindgren JE, Ohlsson A, Widman M, Gillespie H, Hollister L (1986) Pharmacokinetics and metabolism of delta 1-tetrahydrocannabinol and other cannabinoids with emphasis on man. Pharmacol Rev 38:21–43PubMedGoogle Scholar
  2. Aigner TG (1988) Delta-9-tetrahydrocannabinol impairs visual recognition memory but not discrimination learning in rhesus monkeys. Psychopharmacology 95:507–511PubMedCrossRefGoogle Scholar
  3. Angrist BM, Gershon S (1970) The phenomenology of experimentally induced amphetamine psychosis–preliminary observations. Biol Psychiatry 2:95–107PubMedGoogle Scholar
  4. Angrist B, Lee HK, Gershon S (1974a) The antagonism of amphetamine-induced symptomatology by a neuroleptic. Am J Psychiatry 131:817–819PubMedGoogle Scholar
  5. Angrist B, Sathananthan G, Wilk S, Gershon S (1974b) Amphetamine psychosis: behavioral and biochemical aspects. J Psychiatr Res 11:13–23PubMedCrossRefGoogle Scholar
  6. Barnes TR (1989) A rating scale for drug-induced akathisia. Br J Psychiatry 154:672–676PubMedCrossRefGoogle Scholar
  7. Berk M, Brook S, Trandafir AI (1999) A comparison of olanzapine with haloperidol in cannabis-induced psychotic disorder: a double-blind randomized controlled trial. Int Clin Psychopharmacol 14:177–1780PubMedCrossRefGoogle Scholar
  8. Brandt J, Corwin J, Krafft L (1992) Is verbal recognition memory really different in Huntington’s and Alzheimer’s disease. J Clin Exp Neuropsychol 14:773–784PubMedCrossRefGoogle Scholar
  9. Bremner JD, Krystal JH, Putnam FW, Southwick SM, Marmar C, Charney DS, Mazure CM (1998) Measurement of dissociative states with the Clinician-Administered Dissociative States Scale (CADSS). J Trauma Stress 11:125–136PubMedCrossRefGoogle Scholar
  10. Brunner E, Domhof S, Langer F (2002) Nonparametric analysis of longitudinal data in factorial experiments. Wiley, New YorkGoogle Scholar
  11. Budney AJ, Moore BA, Vandrey RG, Hughes JR (2003) The time course and significance of cannabis withdrawal. J Abnorm Psychology 112:393–402CrossRefGoogle Scholar
  12. Bylsma FW, Rebok GW, Brandt J (1991) Long-term retention of implicit learning in Huntington’s disease. Neuropsychologia 29:1213–1221PubMedCrossRefGoogle Scholar
  13. Carlini EA, Hamaoui A, Bieniek D, Korte F (1970a) Effects of (−) delta-9-trans-tetrahydrocannabinol and a synthetic derivative on maze performance of rats. Pharmacology 4:359–368PubMedCrossRefGoogle Scholar
  14. Carlini EA, Santos M, Claussen U, Bieniek D, Korte F (1970b) Structure activity relationship of four tetrahydrocannabinols and the pharmacological activity of five semi-purified extracts of Cannabis sativa. Psychopharmacologia 18:82–93PubMedCrossRefGoogle Scholar
  15. Chen J, Paredes W, Lowinson JH, Gardner EL (1990a) Delta 9-tetrahydrocannabinol enhances presynaptic dopamine efflux in medial prefrontal cortex. Eur J Pharmacol 190:259–262PubMedCrossRefGoogle Scholar
  16. Chen JP, Paredes W, Li J, Smith D, Lowinson J, Gardner EL (1990b) Delta 9-tetrahydrocannabinol produces naloxone-blockable enhancement of presynaptic basal dopamine efflux in nucleus accumbens of conscious, freely-moving rats as measured by intracerebral microdialysis. Psychopharmacology 102:156–162PubMedCrossRefGoogle Scholar
  17. Chen JP, Paredes W, Lowinson JH, Gardner EL (1991) Strain-specific facilitation of dopamine efflux by delta 9-tetrahydrocannabinol in the nucleus accumbens of rat: an in vivo microdialysis study. Neurosci Lett 129:136–180PubMedCrossRefGoogle Scholar
  18. Compton WM, Grant BF, Colliver JD, Glantz MD, Stinson FS (2004) Prevalence of marijuana use disorders in the United States: 1991–1992 and 2001–2002. Jama 291:2114–2121PubMedCrossRefGoogle Scholar
  19. Curran HV, Brignell C, Fletcher S, Middleton P, Henry J (2002) Cognitive and subjective dose-response effects of acute oral Delta 9-tetrahydrocannabinol (THC) in infrequent cannabis users. Psychopharmacology 164:61–70PubMedCrossRefGoogle Scholar
  20. D’Souza DC (2007) Cannabinoids and psychosis. Int Rev Neurobiol 78:289–326PubMedCrossRefGoogle Scholar
  21. D’Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, Braley G, Gueorguieva R, Krystal JH (2004) The psychotomimetic effects of intravenous delta-9-tetrahydrocannabinol in healthy individuals: implications for psychosis. Neuropsychopharmacology 29:1558–1572PubMedCrossRefGoogle Scholar
  22. D’Souza DC, Abi-Saab WM, Madonick S, Forselius-Bielen K, Doersch A, Braley G, Gueorguieva R, Cooper TB, Krystal JH (2005) Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. Biol Psychiatry 57:594–608PubMedCrossRefGoogle Scholar
  23. D’Souza DC, Gil RB, Zuzarte E, MacDougall LM, Donahue L, Ebersole JS, Boutros NN, Cooper T, Seibyl J, Krystal JH (2006) Gamma-aminobutyric acid-serotonin interactions in healthy men: implications for network models of psychosis and dissociation. Biol Psychiatry 59:128–137PubMedCrossRefGoogle Scholar
  24. D’Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, Perry E, Krystal J (2008) Blunted Psychotomimetic and Amnestic Effects of Delta-9-tetrahydrocannabinol in Frequent Users of Cannabis. Neuropsychopharmacology (in press). DOI 10.1038/sj.npp.1301643
  25. Diana M, Melis M, Gessa GL (1998) Increase in meso-prefrontal dopaminergic activity after stimulation of CB1 receptors by cannabinoids. Eur J Neurosci 10:2825–2830PubMedCrossRefGoogle Scholar
  26. Egerton A, Allison C, Brett RR, Pratt JA (2006) Cannabinoids and prefrontal cortical function: insights from preclinical studies. Neurosci Biobehav Rev 30:680–695PubMedCrossRefGoogle Scholar
  27. Fadda P, Scherma M, Spano MS, Salis P, Melis V, Fattore L, Fratta W (2006) Cannabinoid self-administration increases dopamine release in the nucleus accumbens. Neuroreport 17:1629–1632PubMedCrossRefGoogle Scholar
  28. Farde L, Nordstrom AL, Wiesel FA, Pauli S, Halldin C, Sedvall G (1992) Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49:538–544PubMedGoogle Scholar
  29. Fergusson DM, Poulton R, Smith PF, Boden JM (2006) Cannabis and psychosis. Bmj 332:172–175PubMedCrossRefGoogle Scholar
  30. First MB, Spitzer RL, Gibbon M, Williams JBW (2002) Structured clinical interview for DSM-IV-TR Axis I disorders—non-patient edition. American Psychiatric Association, Washington, DCGoogle Scholar
  31. French ED (1997) delta9-Tetrahydrocannabinol excites rat VTA dopamine neurons through activation of cannabinoid CB1 but not opioid receptors. Neurosci Lett 226:159–162PubMedCrossRefGoogle Scholar
  32. French ED, Dillon K, Wu X (1997) Cannabinoids excite dopamine neurons in the ventral tegmentum and substantia nigra. Neuroreport 8:649–652PubMedCrossRefGoogle Scholar
  33. Gardner EL (2005) Endocannabinoid signaling system and brain reward: emphasis on dopamine. Pharmacol Biochem Behav 81:263–284PubMedCrossRefGoogle Scholar
  34. Gessa GL, Melis M, Muntoni AL, Diana M (1998) Cannabinoids activate mesolimbic dopamine neurons by an action on cannabinoid CB1 receptors. Eur J Pharmacol 341:39–44PubMedCrossRefGoogle Scholar
  35. Goldman-Rakic PS (1996) Regional and cellular fractionation of working memory. Proc Natl Acad Sci USA 93:13473–13480PubMedCrossRefGoogle Scholar
  36. Gordon M (1986) Microprocessor-based assessment of attention deficit disorders (ADD). Psychopharmacol Bull 22:288–290PubMedGoogle Scholar
  37. Gregerson KA, Selmanoff M (1988) Selective effects of hyperprolactinemia on in vitro dopamine release from median eminence synaptosomes. J Neurosci 8:2477–2484PubMedGoogle Scholar
  38. Griffith JD, Cavanaugh J, Held J, Oates JA (1972) Dextroamphetamine. Evaluation of psychomimetic properties in man. Arch Gen Psychiatry 26:97–100PubMedGoogle Scholar
  39. Haertzen CA (1965) Addiction Research Center Inventory (ARCI): development of a general drug estimation scale. J Nerv Ment Dis 141:300–307PubMedGoogle Scholar
  40. Haertzen CA (1966) Development of scales based on patterns of drug effects, using the addiction Research Center Inventory (ARCI). Psychol Rep 18:163–194PubMedGoogle Scholar
  41. Haney M (2005) The marijuana withdrawal syndrome: diagnosis and treatment. Curr Psychiatry Rep 7:360–366PubMedCrossRefGoogle Scholar
  42. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW (1999a) Abstinence symptoms following oral THC administration to humans. Psychopharmacology 141:385–394PubMedCrossRefGoogle Scholar
  43. Haney M, Ward AS, Comer SD, Foltin RW, Fischman MW (1999b) Abstinence symptoms following smoked marijuana in humans. Psychopharmacology (Berl) 141:395–404CrossRefGoogle Scholar
  44. Harclerode J (1984) Endocrine effects of marijuana in the male: preclinical studies. In: Braude MC, Ludford JP (eds) NIDA Research Monograph Series. National Institute on Drug Abuse, Rockville, MD, pp 45–114Google Scholar
  45. Heishman SJ, Arasteh K, Stitzer ML (1997) Comparative effects of alcohol and marijuana on mood, memory, and performance. Pharmacol Biochem Behav 58:93–101PubMedCrossRefGoogle Scholar
  46. Henquet C, Murray R, Linszen D, van Os J (2005) The environment and schizophrenia: the role of Cannabis use. Schizophr Bull 31:608–612PubMedCrossRefGoogle Scholar
  47. Henquet C, Rosa A, Krabbendam L, Papiol S, Fananas L, Drukker M, Ramaekers JG, van Os J (2006) An experimental study of catechol-o-methyltransferase Val158Met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 31:2748–2757PubMedCrossRefGoogle Scholar
  48. Hermann H, Marsicano G, Lutz B (2002) Coexpression of the cannabinoid receptor type 1 with dopamine and serotonin receptors in distinct neuronal subpopulations of the adult mouse forebrain. Neuroscience 109:451–460PubMedCrossRefGoogle Scholar
  49. Heyser CJ, Hampson RE, Deadwyler SA (1993) Effects of delta-9-tetrahydrocannabinol on delayed match to sample performance in rats: alterations in short-term memory associated with changes in task specific firing of hippocampal cells. J Pharmacol Exp Ther 264:294–307PubMedGoogle Scholar
  50. Jarrahian A, Watts VJ, Barker EL (2004) D2 dopamine receptors modulate Galpha-subunit coupling of the CB1 cannabinoid receptor. J Pharmacol Exp Ther 308:880–886PubMedCrossRefGoogle Scholar
  51. Jentsch JD, Andrusiak E, Tran A, Bowers MB Jr., Roth RH (1997) Delta 9-tetrahydrocannabinol increases prefrontal cortical catecholaminergic utilization and impairs spatial working memory in the rat: blockade of dopaminergic effects with HA966. Neuropsychopharmacology 16:426–432PubMedCrossRefGoogle Scholar
  52. Jentsch JD, Verrico CD, Le D, Roth RH (1998) Repeated exposure to delta 9-tetrahydrocannabinol reduces prefrontal cortical dopamine metabolism in the rat. Neurosci Lett 246:169–172PubMedCrossRefGoogle Scholar
  53. Kapur S, Zipursky R, Roy P, Jones C, Remington G, Reed K, Houle S (1997) The relationship between D2 receptor occupancy and plasma levels on low dose oral haloperidol: a PET study. Psychopharmacology (Berl) 131:148–152CrossRefGoogle Scholar
  54. Kapur S, Zipursky R, Jones C, Remington G, Houle S (2000) Relationship between dopamine D(2) occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514–520PubMedCrossRefGoogle Scholar
  55. Kay SR, Opler LA, Lindenmayer JP (1989) The Positive and Negative Syndrome Scale (PANSS): rationale and standardisation. Br J Psychiatr Suppl 7:59–67Google Scholar
  56. King DJ (1997) Guidelines for the use of antipsychotic drug studies in healthy volunteers. The BAP Consensus Group. J Psychopharmacol 11:201–209PubMedCrossRefGoogle Scholar
  57. Kinoshita H, Hasegawa T, Katsumata Y, Kameyama T, Yamamoto I, Nabeshima T (1994) Effect of dizocilpine (MK-801) on the catalepsy induced by delta 9-tetrahydrocannabinol in mice. J Neural Transm Gen Sect 95:137–143PubMedCrossRefGoogle Scholar
  58. Kolb B, Gorny G, Limebeer CL, Parker LA (2006) Chronic treatment with Delta-9-tetrahydrocannabinol alters the structure of neurons in the nucleus accumbens shell and medial prefrontal cortex of rats. Synapse 60:429–436PubMedCrossRefGoogle Scholar
  59. Krystal JH, D’Souza DC, Karper LP, Bennett A, Abi-Dargham A, Abi-Saab D, Cassello K, Bowers MB Jr., Vegso S, Heninger GR, Charney DS (1999) Interactive effects of subanesthetic ketamine and haloperidol in healthy humans. Psychopharmacology (Berl) 145:193–204CrossRefGoogle Scholar
  60. Krystal JH, Perry EB Jr., Gueorguieva R, Belger A, Madonick SH, Abi-Dargham A, Cooper TB, Macdougall L, Abi-Saab W, D’Souza DC (2005) Comparative and interactive human psychopharmacologic effects of ketamine and amphetamine: implications for glutamatergic and dopaminergic model psychoses and cognitive function. Arch Gen Psychiatry 62:985–994PubMedCrossRefGoogle Scholar
  61. Krystal JH, Madonick S, Perry E, Gueorguieva R, Brush L, Wray Y, Belger A, D’Souza DC (2006) Potentiation of low dose ketamine effects by naltrexone: potential implications for the pharmacotherapy of alcoholism. Neuropsychopharmacology 31:1793–1800PubMedCrossRefGoogle Scholar
  62. Lane SD, Cherek DR, Lieving LM, Tcheremissine OV (2005) Marijuana effects on human forgetting functions. J Exp Anal Behav 83:67–83PubMedCrossRefGoogle Scholar
  63. Laviolette SR, Grace AA (2006a) Cannabinoids Potentiate Emotional Learning Plasticity in Neurons of the Medial Prefrontal Cortex through Basolateral Amygdala Inputs. J Neurosci 26:6458–6468PubMedCrossRefGoogle Scholar
  64. Laviolette SR, Grace AA (2006b) The roles of cannabinoid and dopamine receptor systems in neural emotional learning circuits: implications for schizophrenia and addiction. Cell Mol Life Sci 63:1597–1613PubMedCrossRefGoogle Scholar
  65. Leweke FM, Schneider U, Thies M, Munte TF, Emrich HM (1999) Effects of synthetic delta9-tetrahydrocannabinol on binocular depth inversion of natural and artificial objects in man. Psychopharmacology (Berl) 142:230–235CrossRefGoogle Scholar
  66. Lichtman AH, Martin BR (2005) Cannabinoid tolerance and dependence. Handb Exp Pharmacol 168:691–717PubMedCrossRefGoogle Scholar
  67. Lichtman AH, Dimen KR, Martin BR (1995) Systemic or intrahippocampal cannabinoid administration impairs spatial memory in rats. Psychopharmacology (Berl) 119:282–290CrossRefGoogle Scholar
  68. Liegeois JF, Ichikawa J, Meltzer HY (2002) 5-HT(2A) receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res 947:157–165PubMedCrossRefGoogle Scholar
  69. Marchese G, Casti P, Ruiu S, Saba P, Sanna A, Casu G, Pani L (2003) Haloperidol, but not clozapine, produces dramatic catalepsy in delta9-THC-treated rats: possible clinical implications. Br J Pharmacol 140:520–526PubMedCrossRefGoogle Scholar
  70. Martin GW, Wilkinson DA, Kapur BM (1988) Validation of self-reported Cannabis use by urine analysis. Addict Behav 13:147–150PubMedCrossRefGoogle Scholar
  71. Meschler JP, Howlett AC (2001) Signal transduction interactions between CB1 cannabinoid and dopamine receptors in the rat and monkey striatum. Neuropharmacology 40:918–926PubMedCrossRefGoogle Scholar
  72. Miyamoto A, Yamamoto T, Ohno M, Watanabe S, Tanaka H, Morimoto S, Shoyama Y (1996) Roles of dopamine D1 receptors in delta 9-tetrahydrocannabinol-induced expression of Fos protein in the rat brain. Brain Res 710:234–240PubMedCrossRefGoogle Scholar
  73. Moghaddam B, Bunney BS (1990) Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J Neurochem 54:1755–1760PubMedCrossRefGoogle Scholar
  74. Moghaddam B, Roth RH, Bunney BS (1990) Characterization of dopamine release in the rat medial prefrontal cortex as assessed by in vivo microdialysis: comparison to the striatum. Neuroscience 36:669–676PubMedCrossRefGoogle Scholar
  75. Murphy BL, Arnsten AF, Goldman-Rakic PS, Roth RH (1996) Increased dopamine turnover in the prefrontal cortex impairs spatial working memory performance in rats and monkeys. Proc Natl Acad Sci USA 93:1325–1329PubMedCrossRefGoogle Scholar
  76. Murphy LL, Munoz RM, Adrian BA, Villanua MA (1998) Function of cannabinoid receptors in the neuroendocrine regulation of hormone secretion. Neurobiol Dis 5:432–446PubMedCrossRefGoogle Scholar
  77. Nagai H, Egashira N, Sano K, Ogata A, Mizuki A, Mishima K, Iwasaki K, Shoyama Y, Nishimura R, Fujiwara M (2006) Antipsychotics improve Delta(9)-tetrahydrocannabinol-induced impairment of the prepulse inhibition of the startle reflex in mice. Pharmacol Biochem Behav 84:330–336PubMedCrossRefGoogle Scholar
  78. Ng Cheong Ton JM, Gerhardt GA, Friedemann M, Etgen AM, Rose GM, Sharpless NS, Gardner EL (1988) The effects of delta 9-tetrahydrocannabinol on potassium-evoked release of dopamine in the rat caudate nucleus: an in vivo electrochemical and in vivo microdialysis study. Brain Res 451:59–68PubMedCrossRefGoogle Scholar
  79. Owen AM, Downes JJ, Sahakian BJ, Polkey CE, Robbins TW (1990) Planning and spatial working memory following frontal lobe lesions in man. Neuropsychologia 28:1021–1034PubMedCrossRefGoogle Scholar
  80. Patel S, Hillard CJ (2003) Cannabinoid-induced Fos expression within A10 dopaminergic neurons. Brain Res 963:15–25PubMedCrossRefGoogle Scholar
  81. Pistis M, Ferraro L, Pira L, Flore G, Tanganelli S, Gessa GL, Devoto P (2002) Delta(9)-tetrahydrocannabinol decreases extracellular GABA and increases extracellular glutamate and dopamine levels in the rat prefrontal cortex: an in vivo microdialysis study. Brain Res 948:155–158PubMedCrossRefGoogle Scholar
  82. Ramaekers JG, Kauert G, van Ruitenbeek P, Theunissen EL, Schneider E, Moeller MR (2006) High-potency marijuana impairs executive function and inhibitory motor control. Neuropsychopharmacology 31:2296–2303PubMedGoogle Scholar
  83. Ranganathan M, D’Souza D (2006) the acute effects of cannabinoids on memory in humans: a review. Psychopharmacology 188:425–444PubMedCrossRefGoogle Scholar
  84. Ranganathan M, Perry E, Braley G, Cooper T, Gueorguieva R, Krystal J, D’Souza DC (2007) Blunted “negative” but not “positive” effects of thc in cannabis abusers: implications for cannabis use in schizophrenia. In: Schulz CTaC (ed) International Congress on Schizophrenia Research. Schizophrenia Bulletin, Colorado Springs, p 477Google Scholar
  85. Robbins TW, James M, Owen AM, Sahakian BJ, McInnes L, Rabbitt P (1994) Cambridge Neuropsychological Test Automated Battery (CANTAB): a factor analytic study of a large sample of normal elderly volunteers. Dementia 5:266–281PubMedGoogle Scholar
  86. Rodriguez De Fonseca F, Fernandez-Ruiz JJ, Murphy LL, Cebeira M, Steger RW, Bartke A, Ramos JA (1992) Acute effects of delta-9-tetrahydrocannabinol on dopaminergic activity in several rat brain areas. Pharmacol Biochem Behav 42:269–275PubMedCrossRefGoogle Scholar
  87. Saeedi H, Remington G, Christensen BK (2006) Impact of haloperidol, a dopamine D2 antagonist, on cognition and mood. Schizophr Res 85:222–231PubMedCrossRefGoogle Scholar
  88. Sahakian BJ, Owen AM (1992) Computerized assessment in neuropsychiatry using CANTAB: discussion paper. J R Soc Med 85:399–402PubMedGoogle Scholar
  89. SAMHSA (2004) Results from the 2003 National Survey on Drug Use and Health: national findings. Substance Abuse and Mental Health Services AdministrationRockville, MDGoogle Scholar
  90. Schotte A, Janssen PF, Gommeren W, Luyten WH, Van Gompel P, Lesage AS, De Loore K, Leysen JE (1996) Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology (Berl) 124:57–73CrossRefGoogle Scholar
  91. Selmanoff M (1981) The lateral and medial median eminence: distribution of dopamine, norepinephrine, and luteinizing hormone-releasing hormone and the effect of prolactin on catecholamine turnover. Endocrinology 108:1716–1722PubMedCrossRefGoogle Scholar
  92. Simpson GM, Angus JW (1970) A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 212:11–19PubMedCrossRefGoogle Scholar
  93. Sobell LC, Sobell MB (1992) Timeline follow-back: a technique for assessing self-reported alcohol consumption. In: Litten R, Allen J (eds) Measuring alcohol consumption. Humana, Totowa, NJ, pp 41–72Google Scholar
  94. Spitzer RL, Williams JBW, Gibbon M, First MB (1990) Structured clinical interview for DSM-III-R-patient edition (SCID-P, version 1.0). American Psychiatric, Washington, DCGoogle Scholar
  95. Tanda G, Pontieri FE, Di Chiara G (1997a) Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science 276:2048–2050PubMedCrossRefGoogle Scholar
  96. Tanda G, Pontieri FE, Di Chiara G (1997b) Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism [comment]. Science 276:2048–2050PubMedCrossRefGoogle Scholar
  97. Verrico CD, Jentsch JD, Roth RH (2003) Persistent and anatomically selective reduction in prefrontal cortical dopamine metabolism after repeated, intermittent cannabinoid administration to rats. Synapse 49:61–66PubMedCrossRefGoogle Scholar
  98. Wachtel SR, ElSohly MA, Ross SA, Ambre J, de Wit H (2002) Comparison of the subjective effects of Delta(9)-tetrahydrocannabinol and marijuana in humans. Psychopharmacology (Berl) 161:331–339CrossRefGoogle Scholar
  99. Wall ME, Brine DR, Perez-Reyes M (1976) Metabolism of cannabinoids in man. In: Braude MC, Szara S (eds) Pharmacology of marihuana. vol. 1. Raven, New York (536pp.)Google Scholar
  100. Winsauer PJ, Lambert P, Moerschbaecher JM (1999) Cannabinoid ligands and their effects on learning and performance in rhesus monkeys. Behav Pharmacol 10:497–511PubMedCrossRefGoogle Scholar
  101. Zahrt J, Taylor JR, Mathew RG, Arnsten AF (1997) Supranormal stimulation of D1 dopamine receptors in the rodent prefrontal cortex impairs spatial working memory performance. J Neurosci 17:8528–8535PubMedGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  • Deepak Cyril D’Souza
    • 1
    • 2
    • 3
    • 5
  • Gabriel Braley
    • 1
    • 3
  • Rebecca Blaise
    • 1
    • 3
  • Michael Vendetti
    • 1
    • 3
  • Stephen Oliver
    • 1
    • 3
  • Brian Pittman
    • 2
  • Mohini Ranganathan
    • 1
    • 3
  • Savita Bhakta
    • 1
    • 3
  • Zoran Zimolo
    • 1
    • 3
  • Thomas Cooper
    • 4
  • Edward Perry
    • 1
    • 3
  1. 1.Schizophrenia Biological Research CenterVA Connecticut Healthcare SystemWest HavenUSA
  2. 2.Abraham Ribicoff Research FacilitiesConnecticut Mental Health CenterNew HavenUSA
  3. 3.Department of PsychiatryYale University School of MedicineNew HavenUSA
  4. 4.Department of Psychiatry, College of Physicians and SurgeonsColumbia UniversityNew YorkUSA
  5. 5.Psychiatry Service, 116AVA Connecticut Healthcare SystemWest HavenUSA

Personalised recommendations